Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Memorial Day. We will reopen on Tuesday, May 30th.

Thank you for your patience.

To Purchase # 8406LC

8406LC 10 µg (With Carrier) $204.00.0
8406LF 10 µg (Carrier Free) $204.00.0
$0.00

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

Source / Purification

Recombinant human TGF-β2 (hTGF-β2) Ala303-Ser414 (Accession #NP_003229) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β2. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hTGF-β2 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,719. DTT-reduced protein migrates as a 12 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 24 kDa protein. The expected amino-terminal ALDAA of recombinant hTGF-β2 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hTGF-β2 was was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.1-0.3 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hTGF-β2.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 35% acetonitrile and 0.1% trifluoroacetic acid containing 20 μg BSA per 1 μg hTGF-β2. Carrier free: Lyophilized from a 0.22 μm filtered solution of 35% acetonitrile and 0.1% trifluoroacetic acid.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

TGF-β2 is produced by eosinophils, astrocytes, glioblastoma and other cancer derived cell types (1-6). TGF-β2 inhibits antigen-induced T-cell proliferation, inhibits epithelial cell proliferation, induces mesenchymal cell proliferation and has cell specific effects on apoptosis (1-8). TGF-β2 binds to TβRII and binding is promoted by TβRIII. TβRI then complexes with TβRII and TβRIII (3,5). Signaling involves phosphorylation of the SMAD proteins (2,3,9). TGF-β2 also activates Erk2, p38, and JNK pathways (9). Knockout of TGF-β2 in mice severely impacts heart, lung and eye development (10).


1.  Balzar, S. et al. (2005) J Allergy Clin Immunol 115, 110-7.

2.  Siegel, P.M. and Massagué, J. (2003) Nat Rev Cancer 3, 807-21.

3.  Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20.

4.  Hinz, S. et al. (2007) Cancer Res 67, 8344-50.

5.  Damstrup, L. et al. (1993) Br J Cancer 67, 1015-21.

6.  Constam, D.B. et al. (1992) J Immunol 148, 1404-10.

7.  Zhang, H. et al. (2008) Immunology 124, 304-14.

8.  Dufour, C. et al. (2008) Am J Physiol Endocrinol Metab 294, E794-801.

9.  Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714.

10.  Dünker, N. and Krieglstein, K. (2000) Eur J Biochem 267, 6982-8.


Entrez-Gene Id 7042
Swiss-Prot Acc. P61812


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

8406
Human Transforming Growth Factor β2 (hTGF-β2)